Olmesartan/Amlodipin 1a Pharma (Olmesartan Medoxomil, Amlodipine)

Olmesartan/Amlodipin acts on the renin‑angiotensin system and vascular smooth muscle to lower blood pressure in hypertensive patients.

• Hypertension: provides sustained reduction of systolic and diastolic blood pressure.
• Essential hypertension: offers consistent control when monotherapy is insufficient.
• Hypertensive patients requiring combination therapy: delivers two complementary mechanisms in a single tablet, improving adherence.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth muscle and cardiac myocytes, causing arterial vasodilation and reduced peripheral resistance. The combined effect results in lowered systemic blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate discomfort often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially after standing.
• Peripheral edema: swelling of ankles or feet due to fluid accumulation.
• Flushing: transient warmth and reddening of the skin.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Myocardial infarction: chest pain or other signs of heart attack.
• Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment.

Patients and prescribers should observe several safety measures before and during treatment.

• Blood pressure monitoring: check regularly to ensure therapeutic targets are met.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with existing kidney disease.
• Hepatic impairment: use caution and consider dose adjustment in severe liver dysfunction.
• Pregnancy: avoid use unless clearly needed; safety data are limited.
• Concomitant potassium‑sparing agents: monitor serum potassium to prevent hyperkalaemia.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipin may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• ACE inhibitors or aliskiren: increased risk of hyperkalaemia and renal impairment.
• Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia.
• Cyclosporine: can raise olmesartan plasma concentrations.
• Simvastatin: amlodipine raises statin levels, increasing risk of myopathy.
• NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: additive blood‑pressure lowering effect, watch for hypotension.
• Rifampin: induces metabolism, potentially reducing amlodipine exposure.
• Digoxin: monitor serum levels as amlodipine may increase concentrations.
• Beta‑blockers: may enhance bradycardia; observe heart rate.